Christopher Luscy, MD
Nephrology · Baton Rouge, LANPI 1255338521
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (54.6%), consulting fees and education — rather than concentrated in one kind of arrangement. 25 manufacturers reported payments, led by Novartis at 42.9% of the total. Reporting peaked in 2023 at $3,318 and has fallen 85.8% since, to $472 in 2025.
Across 171 payments — averaging $37.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$3K
- Fresenius USA Marketing, Inc.$1K
- AstraZeneca$788
- Medtronic$412
- Sanofi$306
- Amgen$141
- plus $863 from 19 others
Across 97 payments — averaging $11,121 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Vertex$608K
- GSK$249K
- Otsuka Pharmaceutical Co., Ltd.$162K
- Novartis$47K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$12K
What the payments were for
- Consulting fees$2,70042%
- Food & beverage$3,51955%
- Education$2253%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 4 | $2,762 |
| Fresenius USA Marketing, Inc. | 61 | $1,172 |
| AstraZeneca | 35 | $788 |
| Medtronic | 18 | $412 |
| Sanofi | 10 | $306 |
| Amgen(2 entities) | 8 | $141 |
| Bayer | 1 | $119 |
| Bard Peripheral Vascular, Inc. | 3 | $107 |
| Otsuka America Pharmaceutical, Inc. | 4 | $81 |
| Amicus Therapeutics, Inc. | 4 | $75 |
| Abiomed | 1 | $60 |
| ANI Pharmaceuticals, Inc. | 3 | $51 |
| Calliditas Therapeutics US Inc. | 2 | $47 |
| Akebia Therapeutics Inc | 2 | $41 |
| Mallinckrodt Hospital Products Inc. | 2 | $39 |
| Vifor Pharma, Inc. | 2 | $34 |
| OPKO Pharmaceuticals, LLC | 2 | $31 |
| Mozarc Medical US LLC | 2 | $30 |
| Daiichi Sankyo Inc. | 1 | $27 |
| W. L. Gore & Associates, Inc. | 1 | $25 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $23 |
| Ultragenyx Pharmaceutical Inc. | 1 | $21 |
| Chiesi USA, Inc. | 1 | $18 |
| Novo Nordisk | 1 | $17 |
| Boehringer Ingelheim | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,444 in reported general payments places this provider in the 80th percentile of 206 nephrology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VelphoroSucroferric Oxyhydroxide | 73 | $210,072 |
| AuryxiaFerric Citrate | 49 | $107,271 |
| ProcritEpoetin Alfa | 23 | $23,650 |
| Lanthanum Carbonate | 18 | $15,334 |
| VeltassaPatiromer Calcium Sorbitex | 20 | $14,729 |
| FarxigaDapagliflozin Propanediol | 19 | $14,685 |
| JardianceEmpagliflozin | 15 | $9,776 |
| Sevelamer Carbonate | 42 | $7,705 |
| Cinacalcet Hcl | 15 | $5,180 |
| MitigareColchicine | 14 | $2,588 |
| Calcitriol | 62 | $1,058 |
| Allopurinol | 26 | $777 |
| Amlodipine Besylate | 97 | $595 |
| Hydralazine Hcl | 36 | $582 |
| Clonidine | 13 | $497 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Fresenius USA Marketing, Inc.Velphoro | $1,172 | $210,07273 claims |
| Akebia Therapeutics IncAuryxia | $41 | $107,27149 claims |
| AstraZenecaFarxiga | $788 | $14,68519 claims |
| Boehringer IngelheimJardiance | $16 | $9,77615 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 206 nephrology providers in Louisiana.
Other nephrology in Baton Rouge
- Jones SamuelBaton Rouge$207K
- Michael RoppoloBaton Rouge$13K
- Robert LandryBaton Rouge$13K
- Raynold CoronaBaton Rouge$12K
- Damodar KumbalaBaton Rouge$10K
- Kiran PadigalaBaton Rouge$6K
- Kenneth SmithBaton Rouge$5K
- James YeggeBaton Rouge$5K
- Mahesh BasireddyBaton Rouge$5K
- William MurrillBaton Rouge$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.